Adding bavituximab to second-line chemotherapy doubles response rate
Patients also had increase in progression free, overall survival rates
2012-09-07
(Press-News.org) Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.
Docetaxel is the standard second-line treatment for stage IIIB and stage IV NS-NSCLC patients. Researchers in this phase II, nine center, double-blind, randomized study evaluated the efficacy and safety of docetaxel plus a placebo (control arm) versus docetaxel plus either 1 mg or 3 mg bavituximab. The 117 evaluable patients were randomized to receive one of the three regimens every 21 days for up to six cycles. Patients received the same regimen for each cycle.
The overall response rate for the 1 mg bavituximab arm was 15 percent and 17.9 percent in the 3 mg arm, approximately double the control arm rate of 7.9 percent. Median progression-free survival was 4.2 and 4.5 months for the bavituximab arms, respectively, compared to three months for the control arm.
The trial was unblinded after 18 months, at which point the median overall survival had been reached in the control arm at 5.4 months (61 percent of patients died); however, neither bavituximab arms had reached median overall survival (fewer than 35 percent of patients died).
"This rigorous phase II trial demonstrates that not only is bavituximab well tolerated when given with docetaxel but it improves response rates, progression free survival and overall survival of second-line chemotherapy in patients with advanced NSCLC," said David Gerber, MD, lead author of the study and an assistant professor of internal medicine at University of Texas Southwestern Medical Center in Dallas who specializes in lung cancer treatment. "If a phase III trial confirms these findings, bavituximab could become a major component of standard treatment for patients with this challenging disease."
###
The abstract, "Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Top-line Results)," will be presented during the Plenary Session at 12:30 p.m., Central time on September 7, 2012. To speak with David Gerber, MD, please call Michelle Kirkwood or Nicole Napoli on September 6-8, 2012, in the press office at the Chicago Marriott Downtown Magnificent Mile at 312-595-3188. You may also send an email to michellek@astro.org or nicolen@astro.org.
ELSE PRESS RELEASES FROM THIS DATE:
2012-09-07
This press release is available in French.Researchers from the Guy Rouleau Laboratory affiliated with the CHUM Research Centre and the CHU–Sainte-Justine Research Centre have discovered the genetic cause of a rare disease reported only in patients originating from Newfoundland: hereditary spastic ataxia (HSA).
This condition is characterized by lower-limb spasticity (or stiffness) and ataxia (lack of coordination), the latter leading to speech and swallowing problems, and eye movement abnormalities. The disease is not deadly, but people start developing gait problems ...
2012-09-07
Stage I, non-small cell lung cancer (NSCLC) patients who received radiation therapy have an increased median survival of 21 months compared to 16 months, and the percentage of patients who receive no treatment declined from 20 percent to 16 percent, respectively, when comparing the two eras evaluated, 1999-2003 and 2004-2008, according to detailed analysis of the SEER-17 (Surveillance Epidemiology and End Results, National Cancer Institute) national database presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the ...
2012-09-07
Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the ...
2012-09-07
TORONTO, Sept. 6, 2012 – Imagine that the players on your favourite football team were smaller than their opponents, and had to play without helmets or pads. Left defenseless, they would become easy prey for other teams. Similarly, changes in Canadian lake water chemistry have left small water organisms vulnerable to their predators, which may pose a serious environmental threat, according to a new study.
"At low calcium levels the organisms grow slower and cannot build their armour," says study lead author Howard Riessen, professor of biology, SUNY College at Buffalo. ...
2012-09-07
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association ...
2012-09-07
SAN ANTONIO (Sept. 6, 2012) — RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.
Santanu Bose, Ph.D., of the School of Medicine, is the inventor on a pending U.S. patent of RSV as an oncolytic therapy. This represents a new use for the virus. Bandana Chatterjee, Ph.D., of the School of Medicine and the South Texas Veterans Health Care System, is the co-inventor. Oncolytic ...
2012-09-07
Every ten years or so, someone will make the observation that there is a lack of political diversity among psychological scientists and a discussion about what ought to be done ensues. The notion that the field discriminates against and is skewed toward a liberal political perspective is worthy of concern; scholars, both within and outside the field, have offered various solutions to this diversity problem.
As psychological scientists Yoel Inbar and Joris Lammers point out, however, we have few of the relevant facts necessary to understand and address the issue.
In ...
2012-09-07
Pick your poison: sun exposure that leads to skin cancer or low physical activity that leads to obesity? In fact, a University of Colorado Cancer Center study published this week in the journal Preventing Chronic Disease shows that parents' concern about skin cancer doesn't make them keep their kids indoors.
"Actually, our hypothesis was the opposite – that if parents were concerned about skin cancer they wouldn't let their children go out as much," says Alexander Tran, summer fellow working with Lori Crane, PhD, CU Cancer Center investigator and chair of the Department ...
2012-09-07
GAINESVILLE, Fla. — University of Florida scientists publishing the first study on butterflies and moths of Guantanamo Bay Naval Station have discovered vast biodiversity in an area previously unknown to researchers.
Appearing in the Bulletin of the Allyn Museum Sept. 5, the study creates a baseline for understanding how different plant and animal species have spread throughout the Caribbean.
"Biodiversity studies are extremely important because they give us clues about where things were and how they evolved over time so we can better understand what may happen in ...
2012-09-07
CAMBRIDGE, MA -- Competition is a strong driving force of evolution for organisms of all sizes: Those individuals best equipped to obtain resources adapt and reproduce, while others may fall by the wayside. Many organisms — mammals, birds and insects, for instance — also form cooperative social structures that allow resources to be defended and shared within a population.
But surprisingly, even microbes, which are thought to thrive only when able to win the battle for resources against those nearest to them, have a somewhat sophisticated social structure that relies on ...
LAST 30 PRESS RELEASES:
[Press-News.org] Adding bavituximab to second-line chemotherapy doubles response rate
Patients also had increase in progression free, overall survival rates
